Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers

ST. LOUIS, Dec. 13, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:  STXS) today announced that the Company has started initial shipments of the Epoch platform, its comprehensive solution for the electrophysiology (EP) lab that is designed to increase efficiency in procedures with a fully-remote, networked robotic and magnetic navigation system.  Initial shipments include system upgrades to the new generation Epoch platform from the Niobe® II navigation system for customers in North America and Europe.  As part of the Epoch upgrades, centers in Europe will also install the Company's Vdrive Duo™ mechanical arm robotic navigation system.  The Vdrive Duo arm allows physicians to remotely manipulate a growing array of devices, such as the loop diagnostic catheter and sheath, while also manipulating the magnetic catheter. 

The Epoch platform is designed to improve efficiency and enhance workflow by allowing the physician to control all aspects of the procedure remotely.  It combines the proven value of remote magnetic catheter control and the efficiency benefits of remote robotic device manipulation with the Vdrive™ mechanical arm.  Additionally, the new Epoch user interface is designed to shorten the learning curve for Stereotaxis' platform, thus addressing the needs of the large commercial market.                                                                                                                           

"The Epoch platform has generated tremendous market excitement since its introduction at the annual Heart Rhythm Society meeting in May," said Michael P. Kaminski, President and CEO of Stereotaxis.  "As expected, the initial wave of commitments is coming from current customers who see the clear benefit to upgrade their system to Epoch.  Additionally, we have experienced a surge in new prospective customers visiting our headquarters to understand how Epoch would fit their EP lab needs.  We are excited about the interest in Epoch from current users and the demand curve for prospective customers, and believe we are poised for strong performance in 2012."

About Stereotaxis             www.stereotaxis.com         www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey Cinema™ Studio then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to attract patients and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The Vdrive Duo is not cleared for sale in the U.S. and is currently under review by the FDA. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, our continued access to capital and financial resources, including our ability to negotiate financing and lending arrangements on terms that are acceptable, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.